OKYO Pharma(US:OKYO) Globenewswire·2026-02-23 16:00Core Viewpoint - OKYO Pharma Limited announced the acceptance of its abstract for presentation at the ARVO 2026 Annual Meeting, highlighting the positive results of its Phase 2a clinical trial for urcosimod, a treatment for neuropathic corneal pain (NCP) [1][4]. Group 1: Clinical Trial Results - The Phase 2a clinical trial of urcosimod demonstrated clinically meaningful pain reduction and quality-of-life improvement in NCP patients, as measured by the Visual Analogue Scale (VAS) [2][3]. - Urcosimod showed potential to help restore corneal nerve structure in patients suffering from NCP [2]. Group 2: Drug Development and Regulatory Status - Urcosimod is the first candidate to receive IND clearance specifically for NCP and has been granted FDA Fast Track designation [3][5]. - Following the positive Phase 2a results, the company plans to initiate a larger multicenter Phase 2b/3 trial involving approximately 150 patients to further evaluate urcosimod's efficacy and safety [3][5]. Group 3: Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for NCP and inflammatory eye diseases, with its shares listed on the Nasdaq Capital Market [9]. - The company aims to discover and develop novel molecules to treat NCP and other ocular diseases, having recently completed a successful Phase 2 trial of urcosimod [9].